ReviewPharmacological reports : PR2025
Protective effect and molecular mechanisms of magnolol in ischemic stroke.
Review in Pharmacological reports : PR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Component Analysis and Mechanism Exploration of Fangji Dihuang Decoction in Treating Ischemic Stroke With Homotherapy for Heteropathy Based on Molecular Networking and Network Pharmacology.Biomedical chromatography : BMC · 2026Article
- Phytochemicals with potential NMDAR-inhibitory activities: a review of neuroprotective mechanisms against excitotoxicity.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
Abstract
The treatment methods for ischemic stroke (IS) are currently limited, posing a significant challenge to global healthcare. Tissue-type plasminogen activator remains the only effective drug for IS, yet its use is restricted by narrow therapeutic windows and potential complications, limiting its benefits to a small fraction of patients. Magnolol, the primary bioactive compound extracted from the bark of Magnolia officinalis, a traditional Chinese medicinal herb, has demonstrated promising neuroprotective properties in IS models. This review synthesizes recent findings regarding the neuroprotective effects of magnolol in IS models. It highlights its advantages across various protective mechanisms, including antioxidant activity, anti-inflammatory effects, inhibition of autophagy, prevention of cell death, protection of the blood-brain barrier, and promotion of neuronal survival. By elucidating these mechanisms, this review highlights the therapeutic potential of magnolol in IS and provides a theoretical foundation for future experimental and clinical studies.
Indexed as
Identifiers
40699274What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.